Associated Genetic Biomarkers
CCAAT/enhancer binding protein, alpha (CEBPA) is a gene that encodes a protein that functions as a transcription factor that contains a leucine zipper and identifies CCAAT motifs in the promoter regions of gene targets. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame insertions and deletions are observed in cancers such as hematopoietic and lymphoid cancers, cervical cancer, and intestinal cancer.
CEBPA is altered in 1.17% of all cancers with lung adenocarcinoma, acute myeloid leukemia, high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in CEBPA are CEBPA Mutation (0.67%), CEBPA Amplification (0.62%), CEBPA Missense (0.53%), CEBPA Deletion (0.05%), and CEBPA Insertion (0.04%) .
CEBPA status serves as an inclusion eligibility criteria in 8 clinical trials, of which 8 are open and 0 are closed. Of the trials that contain CEBPA status as an inclusion criterion, 4 are phase 2 (4 open), 2 are phase 2/phase 3 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).
Trials with CEBPA status in the inclusion eligibility criteria most commonly target acute myeloid leukemia, refractory anemia with excess blasts, acute myeloid leukemia arising from previous myelodysplastic syndrome, chronic myelomonocytic leukemia, and myelodysplastic syndromes .
The most frequent alteration to serve as an inclusion eligibility criterion is CEBPA Biallelic Mutation .
Cytarabine, fludarabine, azacitidine, cyclophosphamide, and daunorubicin are the most frequent therapies in trials with CEBPA as an inclusion criteria .
Significance of CEBPA in Diseases
Acute Myeloid Leukemia +
CEBPA is altered in 4.03% of acute myeloid leukemia patients .
CEBPA is an inclusion criterion in 8 clinical trials for acute myeloid leukemia, of which 8 are open and 0 are closed. Of the trials that contain CEBPA status and acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open), 2 are phase 2/phase 3 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) .
Myelodysplastic Syndromes +
CEBPA is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains CEBPA status and myelodysplastic syndromes as inclusion criteria, 1 is phase 2 (1 open) .
Refractory Anemia With Excess Blasts +
CEBPA is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 1 is open and 0 are closed. Of the trial that contains CEBPA status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.